Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 92

1.

Rapid SIV Env-specific mucosal and serum antibody induction augments cellular immunity in protecting immunized, elite-controller macaques against high dose heterologous SIV challenge.

Patterson LJ, Daltabuit-Test M, Xiao P, Zhao J, Hu W, Wille-Reece U, Brocca-Cofano E, Kalyanaraman VS, Kalisz I, Whitney S, Lee EM, Pal R, Montefiori DC, Dandekar S, Seder R, Roederer M, Wiseman RW, Hirsch V, Robert-Guroff M.

Virology. 2011 Mar 1;411(1):87-102. doi: 10.1016/j.virol.2010.12.033.

2.

Replicating adenovirus-simian immunodeficiency virus (SIV) recombinant priming and envelope protein boosting elicits localized, mucosal IgA immunity in rhesus macaques correlated with delayed acquisition following a repeated low-dose rectal SIV(mac251) challenge.

Xiao P, Patterson LJ, Kuate S, Brocca-Cofano E, Thomas MA, Venzon D, Zhao J, DiPasquale J, Fenizia C, Lee EM, Kalisz I, Kalyanaraman VS, Pal R, Montefiori D, Keele BF, Robert-Guroff M.

J Virol. 2012 Apr;86(8):4644-57. doi: 10.1128/JVI.06812-11.

3.

Mucosal B Cells Are Associated with Delayed SIV Acquisition in Vaccinated Female but Not Male Rhesus Macaques Following SIVmac251 Rectal Challenge.

Tuero I, Mohanram V, Musich T, Miller L, Vargas-Inchaustegui DA, Demberg T, Venzon D, Kalisz I, Kalyanaraman VS, Pal R, Ferrari MG, LaBranche C, Montefiori DC, Rao M, Vaccari M, Franchini G, Barnett SW, Robert-Guroff M.

PLoS Pathog. 2015 Aug 12;11(8):e1005101. doi: 10.1371/journal.ppat.1005101.

4.

Breakthrough of SIV strain smE660 challenge in SIV strain mac239-vaccinated rhesus macaques despite potent autologous neutralizing antibody responses.

Burton SL, Kilgore KM, Smith SA, Reddy S, Hunter E, Robinson HL, Silvestri G, Amara RR, Derdeyn CA.

Proc Natl Acad Sci U S A. 2015 Aug 25;112(34):10780-5. doi: 10.1073/pnas.1509731112.

5.

Enhanced immunity and protective efficacy against SIVmac251 intrarectal challenge following ad-SIV priming by multiple mucosal routes and gp120 boosting in MPL-SE.

Pinczewski J, Zhao J, Malkevitch N, Patterson LJ, Aldrich K, Alvord WG, Robert-Guroff M.

Viral Immunol. 2005;18(1):236-43.

PMID:
15802969
6.

CD40L-adjuvanted DNA/modified vaccinia virus Ankara simian immunodeficiency virus SIV239 vaccine enhances SIV-specific humoral and cellular immunity and improves protection against a heterologous SIVE660 mucosal challenge.

Kwa S, Lai L, Gangadhara S, Siddiqui M, Pillai VB, Labranche C, Yu T, Moss B, Montefiori DC, Robinson HL, Kozlowski PA, Amara RR.

J Virol. 2014 Sep 1;88(17):9579-89. doi: 10.1128/JVI.00975-14.

7.

ALVAC-SIV-gag-pol-env-based vaccination and macaque major histocompatibility complex class I (A*01) delay simian immunodeficiency virus SIVmac-induced immunodeficiency.

Pal R, Venzon D, Letvin NL, Santra S, Montefiori DC, Miller NR, Tryniszewska E, Lewis MG, VanCott TC, Hirsch V, Woodward R, Gibson A, Grace M, Dobratz E, Markham PD, Hel Z, Nacsa J, Klein M, Tartaglia J, Franchini G.

J Virol. 2002 Jan;76(1):292-302.

8.

Immunization of macaques with live simian human immunodeficiency virus (SHIV) vaccines conferred protection against AIDS induced by homologous and heterologous SHIVs and simian immunodeficiency virus.

Kumar A, Mukherjee S, Shen J, Buch S, Li Z, Adany I, Liu Z, Zhuge W, Piatak M Jr, Lifson J, McClure H, Narayan O.

Virology. 2002 Sep 30;301(2):189-205.

9.

Reduction of viral loads by multigenic DNA priming and adenovirus boosting in the SIVmac-macaque model.

Suh YS, Park KS, Sauermann U, Franz M, Norley S, Wilfingseder D, Stoiber H, Fagrouch Z, Heeney J, Hunsmann G, Stahl-Hennig C, Sung YC.

Vaccine. 2006 Mar 10;24(11):1811-20.

PMID:
16274888
10.

Emergence of simian immunodeficiency virus-specific cytotoxic CD4+ T cells and increased humoral responses correlate with control of rebounding viremia in CD8-depleted macaques infected with Rev-independent live-attenuated simian immunodeficiency virus.

von Gegerfelt A, Valentin A, Alicea C, Van Rompay KK, Marthas ML, Montefiori DC, Pavlakis GN, Felber BK.

J Immunol. 2010 Sep 15;185(6):3348-58. doi: 10.4049/jimmunol.1000572.

11.

Recombinant vaccine-induced protection against the highly pathogenic simian immunodeficiency virus SIV(mac251): dependence on route of challenge exposure.

Benson J, Chougnet C, Robert-Guroff M, Montefiori D, Markham P, Shearer G, Gallo RC, Cranage M, Paoletti E, Limbach K, Venzon D, Tartaglia J, Franchini G.

J Virol. 1998 May;72(5):4170-82.

12.

An adenovirus-simian immunodeficiency virus env vaccine elicits humoral, cellular, and mucosal immune responses in rhesus macaques and decreases viral burden following vaginal challenge.

Buge SL, Richardson E, Alipanah S, Markham P, Cheng S, Kalyan N, Miller CJ, Lubeck M, Udem S, Eldridge J, Robert-Guroff M.

J Virol. 1997 Nov;71(11):8531-41.

13.

Preexisting vaccinia virus immunity decreases SIV-specific cellular immunity but does not diminish humoral immunity and efficacy of a DNA/MVA vaccine.

Kannanganat S, Nigam P, Velu V, Earl PL, Lai L, Chennareddi L, Lawson B, Wilson RL, Montefiori DC, Kozlowski PA, Moss B, Robinson HL, Amara RR.

J Immunol. 2010 Dec 15;185(12):7262-73. doi: 10.4049/jimmunol.1000751.

14.

Durable protection of rhesus macaques immunized with a replicating adenovirus-SIV multigene prime/protein boost vaccine regimen against a second SIVmac251 rectal challenge: role of SIV-specific CD8+ T cell responses.

Malkevitch NV, Patterson LJ, Aldrich MK, Wu Y, Venzon D, Florese RH, Kalyanaraman VS, Pal R, Lee EM, Zhao J, Cristillo A, Robert-Guroff M.

Virology. 2006 Sep 15;353(1):83-98.

15.

Rabies virus-based vaccines elicit neutralizing antibodies, poly-functional CD8+ T cell, and protect rhesus macaques from AIDS-like disease after SIV(mac251) challenge.

Faul EJ, Aye PP, Papaneri AB, Pahar B, McGettigan JP, Schiro F, Chervoneva I, Montefiori DC, Lackner AA, Schnell MJ.

Vaccine. 2009 Dec 11;28(2):299-308. doi: 10.1016/j.vaccine.2009.10.051.

16.

Correlation of vaccine-elicited systemic and mucosal nonneutralizing antibody activities with reduced acute viremia following intrarectal simian immunodeficiency virus SIVmac251 challenge of rhesus macaques.

Hidajat R, Xiao P, Zhou Q, Venzon D, Summers LE, Kalyanaraman VS, Montefiori DC, Robert-Guroff M.

J Virol. 2009 Jan;83(2):791-801. doi: 10.1128/JVI.01672-08.

17.

Temporal analyses of virus replication, immune responses, and efficacy in rhesus macaques immunized with a live, attenuated simian immunodeficiency virus vaccine.

Connor RI, Montefiori DC, Binley JM, Moore JP, Bonhoeffer S, Gettie A, Fenamore EA, Sheridan KE, Ho DD, Dailey PJ, Marx PA.

J Virol. 1998 Sep;72(9):7501-9.

18.

Factors associated with slow disease progression in macaques immunized with an adenovirus-simian immunodeficiency virus (SIV) envelope priming-gp120 boosting regimen and challenged vaginally with SIVmac251.

Buge SL, Murty L, Arora K, Kalyanaraman VS, Markham PD, Richardson ES, Aldrich K, Patterson LJ, Miller CJ, Cheng SM, Robert-Guroff M.

J Virol. 1999 Sep;73(9):7430-40.

19.

Passive immune globulin therapy in the SIV/macaque model: early intervention can alter disease profile.

Haigwood NL, Watson A, Sutton WF, McClure J, Lewis A, Ranchalis J, Travis B, Voss G, Letvin NL, Hu SL, Hirsch VM, Johnson PR.

Immunol Lett. 1996 Jun;51(1-2):107-14.

PMID:
8811353
20.

Effects of intestinal survival surgery on systemic and mucosal immune responses in SIV-infected rhesus macaques.

Edghill-Smith YY, Aldrich K, Zhao J, Pinczewski J, Kalyanaraman VS, Johnson M, Heyliger A, Perrin RP, Woodward R, Robert-Guroff M.

J Med Primatol. 2002 Dec;31(6):313-22.

PMID:
12519209

Supplemental Content

Support Center